Barclays analyst Eric Beaumont maintains FirstEnergy (NYSE:FE) with a Equal-Weight and lowers the price target from $49 to $41.
Longeveron Announces Pricing For Rights Offering And Expected Calendar; Rights Offering Priced At A $3.00 Subscription Price Per Share
Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as
